TD BUY $VVUS at 3.67, Supp 3.67 Resis 4.33 R18 HiLo 42% T1Y 10 none fwdPE -1.4 DIV N/A #VIVUS, Inc #stocks #trading #finance #market http://bit.ly/ $VVUS $ITI $SLNO Make profit with good tread and best chatroom, join with us improve your skills and successful trade.. stocktwits.com/JessicaHoff/. Find the latest VIVUS, Inc. (VVUS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. VIVUS, Inc. (VVUS). Today's Latest Price: $1.18 USD. 0.13 (11.90%). Updated May 5 3:25pm. Add VVUS to Watchlist · Sign Up
9 Sep 2015 Activist investor Carl Icahn is jumping into the biopharma fray once again, this time getting involved with struggling obesity drugmaker Vivus. Exploring VIVUS (NASDAQ:VVUS) stock? View VVUS's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at StockTwits: https://stocktwits.com/DrTranBioSci. Harvest Exchange: If you need more information about Site or notice, please address Us using the following
Find the latest VIVUS, Inc. (VVUS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in VVUS: First Quarter 2020 Results: May 7: Edited Transcript of VVUS earnings conference call or presentation 6-May-20 8:30pm GMT: May 7: VIVUS, Inc's (VVUS) CEO John Amos on Q1 2020 Results - Earnings Call Transcript: May 6: Vivus EPS beats by $0.31, beats on revenue: May 6: VIVUS Reports First Quarter 2020 Financial Results: May 1 VVUS Stock Summary. Vivus Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 5.59% of US listed stocks. Equity multiplier, or assets relative to shareholders' equity, comes in at -3.65 for Vivus Inc; that's greater than it is for merely 3.6% of US stocks. At Yahoo Finance, you get free stock quotes, the latest news, portfolio management resources, international market data, social interaction and mortgage rates to help you manage your financial life. vivus inc (vvus): * vivus announces updated agreement with icahn enterprises holdings l.p. * vivus (vvus) - co will continue to work with ieh biopharma on exclusive basis in respect of any restructuring, financing, other material transaction.* vivus (vvus) - if co is unable to refinance on or before june 30, co and ieh biopharma shall exclusively pursue an in court plan of reorganization.
VVUS: First Quarter 2020 Results: May 7: Edited Transcript of VVUS earnings conference call or presentation 6-May-20 8:30pm GMT: May 7: VIVUS, Inc's (VVUS) CEO John Amos on Q1 2020 Results - Earnings Call Transcript: May 6: Vivus EPS beats by $0.31, beats on revenue: May 6: VIVUS Reports First Quarter 2020 Financial Results: May 1 VVUS Stock Summary. Vivus Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 5.59% of US listed stocks. Equity multiplier, or assets relative to shareholders' equity, comes in at -3.65 for Vivus Inc; that's greater than it is for merely 3.6% of US stocks.
Northwest Biotherapeutics, Inc. NWBO 0.38 0.01 (3.59%). NASDAQ Updated Jun 8, 2020 7:59 PM